KalshiComprobar disponibilidadKYC requerido2% de comisiónProbabilidad implícita actualBefore Jan 1, 2027 17%-11.0%Líder entre 5 opciones
Calidad del mercado
28 / 100
Baja calidadVolumen 24h
5,1 €
Liquidez
73,8 €
Baja liquidezCompra / Venta
16.0% / 19.0%
Spread
18.8%
Spread amplioDatos de mercado
Actualizado hace 7 minutos
14 may 26, 2:001 ene 27, 4:59
Tendencias
Resultado elegido
Before Jan 1, 202717%
También disponible en Polymarket
FDA approves Retatrutide this year?
1.0%6m
-0.0%12%
+0.0%89%
52 • Calidad mediaSpread amplioLiquidez media
Volumen total493,2 mil €
Volumen 24h238,8 €
POLYMARKETReglas
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals:
Las probabilidades pueden diferir debido a diferentes estructuras de mercado, comisiones y grupos de participantes.
Mercados Relacionados
Hantavirus pandemic in 2026?
145,3 mil €Sí: 5%POLYMARKET
POLYMARKET
New pandemic in 2026?
16,6 mil €Sí: 10%POLYMARKET
POLYMARKET
How many movies will gross >$1 billion in 2026?
1,3 mil €0-3: 5.7%MANIFOLD MARKETS
MANIFOLD MARKETSWhich disease will be eradicated next in humans?
462,5 €Polio: 26.7%MANIFOLD MARKETS
MANIFOLD MARKETS
When, where or how will Trump die?
137,8 €2025: 0%MANIFOLD MARKETS
MANIFOLD MARKETSActivos en estos temas
Noticias Relacionadas
Chainalysis reveals $100 million peptide market built on cryptoCrypto News
Gray peptide vendors embrace stablecoins as safety fears deepenCrypto News
OpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.News
Brian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto NewsReglas
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: